Expert Perspectives on Diagnosis and Treatment of OAB: A Roundtable Discussion

Urologist Benjamin Brucker, MD, urogynecologist Eman Elkadry, MD, and nurse practitioner Jenna Horton, NP introduce themselves, outline their credentials, and briefly describe the patients with overactive bladder (OAB) who they typically see in their clinical practice.

Experts begin their panel discussion on OAB by describing the typical diagnostic process and initial conversations that they have with patients suspected of having the condition.

Panelists further expand on the typical clinical characteristics of patients with OAB who they see in their practice, common signs and symptoms, and potential differential diagnoses.

A brief overview of how and when providers incorporate urodynamic testing as part of the diagnostic workup for OAB.

Panelists introduce the available treatment modalities for OAB, including behavioral modification, pharmacologic treatment, neuromodulation, and surgical approaches.

A comprehensive discussion on clinical factors that impact pharmacologic treatment selection in patients with OAB.

Experts outline their clinical approach to identifying treatment failure in patients on initial pharmacologic treatment for OAB and strategies for subsequent treatment selection.

Shared insight on strategies used to converse with and educate patients on pharmacologic treatment options for OAB, including the potential for adverse events tied to therapy.

Panelists identify key goals of therapy when treating OAB and identify resources that may aid in patient education.

Experts provide their perspective on the advent of third-line therapy in OAB and discuss details in the clinical process of transitioning patients out of the second-line setting.

Focused discussion on effectively communicating expectations for third-line therapies with patients being treated for OAB.

An overview of patient monitoring strategies experts use to establish individualized followup with patients receiving therapy for OAB in the third-line setting.

Experts close their panel on OAB by identifying treatment pathways for patients who have an unsatisfactory response to third-line therapy.